Granules India is currently trading at Rs. 329.30, up by 8.95 points or 2.79% from its previous closing of Rs. 320.35 on the BSE.
The scrip opened at Rs. 322.70 and has touched a high and low of Rs. 329.35 and Rs. 322.00 respectively. So far 9504 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 331.80 and Rs. 314.00 respectively. The current market cap of the company is Rs. 7753.84 crore.
The promoters holding in the company stood at 41.93%, while Institutions and Non-Institutions held 26.67% and 31.40% respectively.
Granules India has entered into a strategic partnership with Greenko ZeroC to collaborate for Green Molecule Solutions and its wider applications in pharmaceuticals to build a leadership position in sustainability and circular economy initiatives and be a pioneer in the industry.
Granules & Greenko ZeroC will develop and promote State-of-the-art Integrated Green Pharmaceutical Zones (GPZ) with first collaboration in Kakinada, Andhra Pradesh.
Granules will build a green field facility based on sustainability principles for large scale manufacturing of key starting materials (KSMs), Intermediates, APIs and fermentation-based products.
The facility spread across 100 acres, will be commissioned in a phase wise manner. The estimated cost of the project will be approximately Rs 2,000 crore over five years.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).